This biotech could be high risk, high reward picks according to Bell Potter. The post Why Mesoblast shares could rise 40% in ...

CEO Jeremy Steele is unfazed by humankind’s next frontier in medical science, courtesy of Tesla founder and 500-billion-dollar man Elon Musk.